RECEIVED

©ENTRAL FAX CENTER

APR 0 5 2005

SCHERING-PLOUGH CORPORATION

LAW DEPARTMENT

2000 GALLOPING HILL ROAD K-6-1, MAIL STOP 1990

KENILWORTH, NEW JERSEY 07033

(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO: Examiner: E. O. Sackey USPTO	fax number: (571) 273-8300		
FROM: Palaiyur S. Kalyanaraman	PIIONE NUMBER. (908) 298–5068		
TOTAL NO. OF PAGES INCLUDING COVER 5	DATH April 5, 2005		

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:

PLEASE HAND DELIVER

In re Application of: Zhaoning Zu et al.

For Patent entitled: "Compounds for the Treatment of Inflammatory Disorders"

Group Art Unit: 1626 Filed: 11/19/2003

Attorney Docket No.: IN01535KB

Serial No.: 10/716,890

Dear Examiner Sackey:

Transmitted herewith are:

- ➤ Fax Cover Sheet 1pg.
- Response Transmittal 1pg.
- Response 3pgs.

Palaiyur S. Kalyanaraman Registered Representative Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

Express Mail Label No.

xpress Mail Label No.					PTO/SB/21 (09-04)	
		u.s.	Patent and Tr	ademack Office:	through 07/31/2006. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE.	
Under the Paperwork Red	luction! Act of 1995 no parsons	Application Number	10/716,8	mon muess u uc	solave a valid OMB control number.	
TRANS	MITTAL	Filing Date	11/19/20			
	RM	First Named Inventor	Zhaoning		 	
	1 4141	Art Unit	1626			
		Examinar Name		-1		
(to be used for all correspondence after initial filing)		Altorney Docket Number		E. O. Sackey		
Total Number of Pages in	This Submission 5	7 marriery Brance (10 mbs.)	IN01535	KB		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Reply After Final After Final After Final Extension of Time Request Information Disclosure Statament Certified Copy of Priority Document(s) Fee Attached Licensing-related Papers Petition Patition Patition to Convert to a Provisional Application Power of Allorney, Revocal Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Companies Remarks		Status Letter Other Enclosure(s) (please Identify below):				
	llssing Parts CFR 1.52 or 1.53	OF ADDUCANT ATTO	BUEV O	D. A.C.ENT		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
T IIII Name						
Signature	8le_					
Printed name Palaiyur S. Kalyanaraman						
Date 04/05/2	2005		Reg. No.	34,634		
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature SA De						
Typed or printed name	Palaiyur S. Kalyanaı	raman		Date	04/05/2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and/.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED I TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ifyou need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Ø 003

APR 0 5 2005

PATENT CASE: IN01535KB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zhaoning Zhu et al : Examiner: E. O. Sackey

Application No.: 10/716,890 : Group Art Unit: 1626

Filed: 11/19/2003

For: Compounds for the Treatment:

of Inflammatory Disorders

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

Sir:

This communication is in response to the Office Action issued on March 10, 2005 in the subject case. This communication is being faxed to the Examiner's attention at 571-273-8300.

Claims 2-57 and 59-72 are pending in the case. The Examiner restricted the claims into three groups:

Group I: Claims 2-57, 59-60 and 66-67 drawn to compounds and compositions;

Group II: Claims 61-65 drawn to methods of treating various diseases employing the compounds of Group I; and

Group III: Claims 68-72 drawn to methods of treating various disease employing compounds now allowed in Patent number 6,838,466.

Applicants are puzzled by the restriction into these three Groups.

Applicants believe that all claims form part of one and the same invention.

Applicants further believe that when there is a linking claim encompassing the scope of all the processes, uses, composition and compounds, it is inappropriate to restrict the invention into these various inventions. Applicants also believe that due to such commonality, a complete examination of all the claims as filed would not cause undue burden. Applicants further believe that

2

the same art search will most probably apply to the alleged separate inventions, and respectfully submit that the restriction is improper.

Under the statute "two or more independent and distinct inventions.... in one application may.... be restricted to one of the inventions." Inventions are "independent" if " there is no disclosed relationship between two or more subjects disclosed" (MPEP 802.01). The term "distinct" means that "two or more subjects as disclosed are related.... but are capable of separate manufacture, use or sale as claimed, and are patentable over each other" (MPEP 802.01). However, even when patentably distinct inventions, restriction is not required unless one of the following reasons appear (MPEP 808.02):

- 1. Separate classification
- 2. Separate status in the art; or
- 3. Different field of search.

In the present application, Applicant believes that the Examiner has not established a clear reason to establish the existence of any of the above 3 groups. Reconsideration and withdrawal of the restriction requirement are, therefore, respectfully requested.

3

Furthermore, in order to comply with the Examiner's requirement,
Applicant is electing, with traverse, the invention cited as Invention Group No.
III by the Examiner for initial examination purposes. Additionally, since the
Examiner required election of a species, Applicant provisionally elects, with
traverse, the compound of Formula:

(shown as Example KX in Table 1 at page 126 and in claim 57 at page 170 of the specification) for initial examination in this application.

If the Examiner has questions, as well as for any future communications, the Examiner is invited to contact the undersigned.

April 5, 2005 Schering-Plough Corporation 2000 Galloping Hill Road Patent Department, K-6-1, 1990 Kenilworth, NJ 07033

Tel: (908) 298-5068 Fax: (908) 298-5388 Respectfully submitted,

Dr. Palaiyur S. Kalyanaraman Attorney for Applicants

Reg. No. 34,634